The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation and pregnancy rate in patients with Polycystic Ovary Syndrome
The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation and pregnancy rate in patients with Polycystic Ovary Syndrome.
Ahmed Maged
120 participants
Sep 1, 2012
Interventional
Conditions
Summary
to assess the adjuvant effect of metformine and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with PCOS
Eligibility
Inclusion Criteria1
- women with PCOS trying to fall pregnant
Exclusion Criteria6
- women with endocrinological abnormalities as thyroid dysfunction or abnormal prolactin levels
- women with hypothalamic or pituitary dysfunctions
- women with other causes of infertility as tubal factor, abnormal uterine cavity and male factor evaluated.
- Women with ovarian cysts
- women with allergy to used medications.
- Patients who had received any hormonal medications (except progesterone for withdrawal bleeding) for at least 3 months before the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
120 women with PCOS were randomly divided to 3 groups: group I (40 women) received clomiphene citrate (CC) only100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle, group II (40 women) received CC 100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle plus N-acetyl cysteine (NAC) 1200 mg orally in two divided doses in the form of powder inserted in small pockets to be diluted into one standard glass of water from day 3 until day 7 of the menstrual cycle and group III (40 women) received CC 100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle plus metformin 500 mg orally three times daily continuously for 4 weeks Monitoring through A transvaginal ultrasonography (TVS) using Toshiba femio 5 (Toshiba Medical Solutions Inc., Ultrasound Division, Japan) equipped with a 6.5 MHz transvaginal transducer on alternate days starting from cycle day 9 till ovulation to determine the follicular number, size, endometrial thickness and pattern and evidence of follicular rupture.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000697684